2 completed, 1 recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Recruiting 1 |
Follow Microscopic Polyangiitis (MPA): new trials by email Literature Review of Microscopic Polyangiitis (MPA) trials Research Report on Microscopic Polyangiitis (MPA)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safe Effective Therapy With Low-Dose Glucocorticoid in ANCA-Associated Vasculitis (SAFE-LOW) Cyclophosphamide, Standard of Care (SOC), Prednisone - Granulomatosis With Polyangiitis, Microscopic Polyangiitis (MPA) | Phase 3 | Recruiting | Ottawa Hospital Research Institute | 36 | 2025-11-10 | 2026-01-30 |
| Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis Rituximab, placebo - Microscopic Polyangiitis (MPA) | Phase 3 | Completed | Assistance Publique - Hôpitaux de Paris | 8 | 2020-10-24 | 2026-05-06 |
| Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis Plasma Exchange, No Plasma Exchange, Glucocorticoids [Standard Dose] - Granulomatosis With Polyangiitis (Wegener's) (GPA), Microscopic Polyangiitis (MPA) | Phase 3 | Completed | University of Pennsylvania | 704 | 2010-05-01 | 2020-05-26 |
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (3) · Microscopic Polyangiitis (3) · Granulomatosis with Polyangiitis (2) · Vasculitis (2)
Autoimmune Diseases (3) · Brain Diseases (3) · Cardiovascular Diseases (3) · Central Nervous System Diseases (3) · Cerebral Small Vessel Diseases (3) · Cerebrovascular Disorders (3) · Immune System Diseases (3) · Nervous System Diseases (3) · Skin Diseases (3) · Skin Diseases, Vascular (3) · Skin and Connective Tissue Diseases (3) · Systemic Vasculitis (3) · Vascular Diseases (3) · Lung Diseases (2) · Lung Diseases, Interstitial (2)
Rituximab (2) · Cyclophosphamide (1) · Glucocorticoids (1) · Plasma Exchange (1) · Prednisone (1) · Standard of Care (1)
Assistance Publique - Hôpitaux de Paris (1) · Ottawa Hospital Research Institute (1) · University of Pennsylvania (1)
Canada (2) · France (2) · Australia (1) · Belgium (1) · Czechia (1) · Denmark (1) · Greece (1) · Italy (1) · Japan (1) · Mexico (1) · New Zealand (1) · Norway (1) · Sweden (1) · United Kingdom (1) · United States (1)
David Jayne, MD (1) · David Massicotte-Azarniouch, MD, MSc (1) · Luc Mouthon, MD PhD (1) · Michael Walsh, MD (1) · Peter Merkel, MD, MPH (1)
PMID 32053298, PMID 36155131, PMID 38346237
2009 (1), 2018 (1)